IDH2 and central nervous system cancer: EGFR amplification was also observed to be limited to IDH wildtype (26%) and TERT mutant (27%) gliomas, occurring irrespective of MGMT promoter methylation status and being mutually exclusive with 1p/19q co-deletion (LOH) [73].